A team at Huntsman Cancer Institute at the University of Utah (the U) has uncovered a previously unrecognized molecular ...

CAMBRIDGE, Mass., April 9, 2026 /PRNewswire/ -- Deck Bio today launches with a multi-target approach designed to expand the reach of T cell engagers in solid tumors by addressing tumor heterogeneity ...

The final AP Top 25 poll of the 2025-26 college basketball season was released Tuesday. To no surprise, Michigan finished the season at No. 1 after completing one of the most dominant NCAA Tournament ...

The FDA has delayed its target decision date for Orca Bio’s blood cancer cell therapy candidate Orca-T by three months to July 6. The review extension comes after the company submitted additional data ...

BERKELEY, CA, March 10, 2026 (EZ Newswire) -- R3 Bio announced the release of its 2026 research report outlining early-stage progress in developing integrated, stem cell-derived biological platforms ...

New simulator and computational tools generate realistic ‘virtual tissues’ and map cell-to-cell ‘conversations’ from spatial transcriptomics data, potentially accelerating AI-driven discoveries in ...

Orca Bio has disclosed $250 million in funding, flooding its balance sheet with cash to buoy preparations for the commercialization of a blood cancer cell therapy. California-based Orca filed for FDA ...

New stem cell-based embryo model reveals previously unknown communication between early tissues that become the spine and muscles in the central part of the body. From the moment an embryo starts to ...

– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class ...

Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. Down the line, Adagene could make up to $840 million in development and commercial ...

New functional biology platform enables high-plex analysis of cell-cell interactions directly in patient-derived FFPE samples Techstart Early Access Program offers selected partners the opportunity to ...

Treatment with programmed cell death 1/programmed cell death ligand 1 inhibitors for Kaposi sarcoma: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...